Evidence map›Paper›PMID 37081011›Full record

ArticleScientific reports2023

Evaluation of the registry DIALYREG for the assessment of continuous renal replacement techniques in the critically ill patient.

M González-Fernández, N Quílez-Trasobares, J A Barea-Mendoza, Z Molina-Collado, D Arias-Verdú, J Barrueco-Francioni, G Seller-Pérez, M E Herrera-Gutiérrez, J A Sánchez-Izquierdo Riera

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

M González-FernándezDepartment of Intensive Care Medicine, University Hospital 12 de Octubre, Madrid, Spain.
N Quílez-TrasobaresDepartment of Intensive Care Medicine, University Hospital 12 de Octubre, Madrid, Spain.
J A Barea-MendozaDepartment of Intensive Care Medicine, University Hospital 12 de Octubre, Madrid, Spain.
Z Molina-ColladoDepartment of Intensive Care Medicine, University Hospital 12 de Octubre, Madrid, Spain.
D Arias-VerdúDepartment of Intensive Care Medicine, Regional University Hospital of Malaga, Malaga, Spain.
J Barrueco-FrancioniDepartment of Intensive Care Medicine, Regional University Hospital of Malaga, Malaga, Spain.
G Seller-PérezDepartment of Intensive Care Medicine, Regional University Hospital of Malaga, Malaga, Spain.
M E Herrera-GutiérrezDepartment of Intensive Care Medicine, Regional University Hospital of Malaga, Malaga, Spain. mehguci@gmail.com.
J A Sánchez-Izquierdo RieraDepartment of Intensive Care Medicine, University Hospital 12 de Octubre, Madrid, Spain.
Research Institute Hospital 12 de Octubre · ESHospital Regional Universitario de Málaga · ESInstituto de Investigación Biomédica de Málaga · ESUniversidad de Málaga · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Continuous renal replacement techniques (CRRT) can induce complications and monitoring is crucial to ensure patient safety. We designed a prospective multicenter observational and descriptive study using the DIALYREG registry, an online database located on a REDCap web-based platform that allows real-time data analysis. Our main objective was to identify CRRT-related complications in our intensive care units (ICUs) and implement security measures accordingly. From January 2019 to December 2020, we included 323 patients with admission diagnoses of medical illness (54%), sepsis (24%), postoperative care (20%), and trauma (2%). CRRT indications were homeostasis (42%), oliguria (26%), fluid overload (15%), and hemodynamic optimization (13%). The median initial therapy dose was 30 ml/kg/h (IQR 25-40), and dynamic adjustment was performed in 61% of the treatments. Sets were anticoagulated with heparin (40%), citrate (38%) or no anticoagulation (22%). Citrate anticoagulation had several advantages: more frequent dynamic CRRT dose adjustment (77% vs. 58% with heparin and 56% without anticoagulation, p < 0.05), longer duration of set (median of 55 h, IQR 24-72 vs. 23 h, IQR 12-48 with heparin and 12 h, IQR 12-31 without anticoagulation, p < 0.05), less clotting of the set (26% vs. 46.7% with heparin, p < 0.05), and lower incidence of hypophosphatemia (1% citrate vs. 6% with heparin and 5% without anticoagulation). It was also safe and effective in subgroup analysis of patients with liver disease or sepsis. The main global complications were hypothermia (16%), hypophosphatemia (13%) and metabolic acidosis (10%). Weaning of the therapy was achieved through early discontinuation (56%), nocturnal therapy transition (26%) and progressive SLED (18%). 52% of the patients were discharged from the hospital, while 43% died in the ICU and 5% died during hospitalization. We can conclude that the DIALYREG registry is a feasible tool for real-time control of CRRT in our ICU.

Indexed as

Acute Kidney InjuryHypophosphatemiaAnticoagulantsCitratesCitric AcidCritical IllnessHeparinHumansProspective StudiesAnticoagulantsCitratesCitric AcidHeparin

Identifiers

PMID37081011
PMCPMC10117243
OpenAlexW4366589818

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.